Organic Process Research & Development 2001, 5, 622−629
Synthesis of Injectable Antifungal Sch 59884
Gary M. Lee, Jefrey Eckert, Dinesh Gala,* Martin Schwartz, Paul Renton, Edward Pergamen, Michael Whttington,
Doris Schumacher, Larry Heimark, and Petia Shipkova
Chemical Process Research and DeVelopment, Schering-Plough Research Institute, 1011 Morris AVenue,
Union, New Jersey 07083, U.S.A.
Abstract:
unstable to the oxidation conditions, the use of these reagents
was deemed incompatible for the preparation of 1. Either
the cost of the commercially available pentavalent phospho-
rylating reagents or the conditions required for the removal
of the protecting groups inherent in them (incompatible with
Sch 59884 stability) deterred us from using them. Since
hydrogenolysis was known to be compatible with Sch
56592,2 we chose dibenzyl phosphate as the preferred
phosphate moiety for the preparation of 1. Initially direct
phosphorylation of 3 with dibenzylchlorophosphate (DBCP,
its preparation described later in this contribution) was
attempted with the expectation that the mixed anhydride
formed from the reaction of 3 and DBCP could eventually
be hydrolyzed to the desired phosphoester 6, or ideally, the
mixed anhydride could be used to for the direct synthesis of
7. In reality these attempts led to a mixture of inseparable
products, and this approach was abandoned. Next, a literature
survey revealed no example for the selective protection of
alcohol function of 3. At this stage conditions reported3 for
the carboxylic acid moiety protection of amino acids were
applied to 3. Thus, reaction of p-nitrobenzylbromide with 3
resulted in the formation of 4. Although the major product
of this reaction was the desired product 4, several intensely
colored byproducts also formed, and purification of 4 from
this reaction mixture via a plant-friendly procedure proved
difficult. Thus, it was decided to progress with crude 4 for
its subsequent coupling with DBCP.
A synthesis for the preparation of multikilogram quantities of
the injectable antifungal Sch 59884 is described.
Opportunistic fungal infections in immune compromised
individuals have resulted in a renewed interest in potent
antifungals. These infections can cause swallowing difficul-
ties in these individuals, and therefore injectable antifungals
are desirable. Sch 59884, 1, is one such potent azole
injectable antifungal,1 and large amounts of this phosphate
were needed to further evaluate its potential as an injectable
antifungal. We describe here our work towards the develop-
ment of a practical synthetic route which allowed for the
preparation of multikilogram batches 1.
Sch 59884 is derived from the oral antifungal Sch 56592,
2.2 This compound is comprised of four stereogenic centers,
two of which emanate from the synthetically challenging 2,4-
substituted tetrahydrofuran moiety. As such, its preparation
is lengthy and expensive. To minimize the economic burden
of the preparation of 1, it was necessary that incorporation
of 2 should come at a late stage, and that the subsequent
synthetic transformations should be very high-yielding. This
reasoning led to the convergent synthesis of 1 which is shown
in Scheme 1.
The availability of 4-hydroxy sodium butyrate, 3, made
it a suitable starting material for the preparation of 1. For
the phosphate moiety, many commercially viable trivalent
as well as pentavalent phosphorylating reagents were con-
sidered. The trivalent reagents phosphorylate well, and they
would require subsequent oxidation. Since Sch 56592 is
DBCP is a commercially unavailable, reactive, unstable
reagent.4,5 Several methods for its preparation have been
reported.4a-e On the basis of our laboratory work it was
concluded that the method described in ref 4a could be scaled
up, it would not require purification of unstable DBCP, and
it did not generate hazardous waste. Hence, this procedure
was optimized for a scale-up in the plant. Calorimetric
evaluation of the literature procedure for its preparation via
the addition of N-chlorosuccinamide (NCS) to a cold (0 °C)
(3) Perich, J. W.; Alewood, P. F.; Johns, R. B. Aust. J. Chem. 1991, 44, 253.
(4) (a) Atherton, F. R. Biochem. Prep. 1957, 5, 1. (b) Asai, S.; Nakamura, H.;
Tanabe, M.; Sakamoto, K. Ind. Eng. Chem. Res. 1994, 33, 1687. (c)
Silverberg, L. J.; Dillon, J. L.; Vemishetti, P.; Sleezer, P. D.; Discordia, R.
P.; Hartung, K. B.; Gao, Q. Org. Process Res. DeV. 2000, 4, 34. (d)
Silverberg, L. J.; Dillon, J. L.; Vemishetti, P. Tetrahedron Lett. 1996, 37,
771. (e) Oza V. B.; Corcoran, R. C. J. Org. Chem. 1995, 60, 3680.
(5) (a) Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.;
John Wiley and Sons: West Sussex, England, 1995; Vol. 3, p 1536. (b)
Kenner, G. W.; Todd, A. R.; Weymouth, F. J. J. Chem. Soc. 1952, 3675.
(c) Atherton, F. R.; Howard, H. T.; Todd, A. R. J. Chem. Soc. 1948, 1106.
(d) Personal communication with manufacturer of phosphorous reagents
suggested that traces of benzyl alcohol can trigger an autodecomposition
of DBCP. Thus, it was deemed safe to consume this reagent immediately
after its preparation.
(1) (a) Bennett, F.; Ganguly, A.; Girijavallabhan, V. M.; Patel, N. M.; Saksena,
A. K. New Piperazinyl-phenyl Triazolyl-4-hydroxybutanoate Compound
Useful for Treating Systemic Fungal Infections. U.S. Patent 6,043,245,
March 28, 2000. (b) Girijavalabhan, V. M.; Bennett, F.; Saksena, A. K.;
Lovey, R. G.; Wang, H.; Pike, R. E.; Patel, N.; Loebennerg, D.; Nomier,
A. A.; Lin, C. C.; Ganguly, A. K. Sch 59884, A Water-Soluble Prodrug of
Sch 56592 for Intravenous Formulations. Interscience Conference on
Antimicrobial Agents and Chemotherapy; American Society for Microbi-
ology: Washington, DC, 1999, Paper 1932.
(2) Andrews, D. R.; Gala, D.; Gosteli, J.; Gunter, F.; Mergelsberg, I.; Sudhakar,
A. Process for the Preparation of Triazolones. U.S. Patent 5,625,064, April
29, 1997.
622
•
Vol. 5, No. 6, 2001 / Organic Process Research & Development
10.1021/op010212w CCC: $20.00 © 2001 American Chemical Society and The Royal Society of Chemistry
Published on Web 10/12/2001